BofA raised the firm’s price target on Argenx (ARGX) to $774 from $770 and keeps a Buy rating on the shares. The company pre-announced Q4 Vyvgart revenue ahead of expectations, notes the analyst, who is “encouraged” by the continued strong momentum of Vyvgart in generalized myasthenia gravis and positive initial metrics in chronic inflammatory demyelinating polyneuropathy, adding that it increased its near-term revenue estimates to reflect continued growth in the franchise.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx downgraded to Sell at Deutsche Bank on unfavorable risk/reward
- Argenx downgraded to Sell from Hold at Deutsche Bank
- Argenx price target raised to $717 from $670 at H.C. Wainwright
- Argenx price target raised to $700 from $660 at Truist
- Argenx price target raised to $696 from $606 at JMP Securities